Human Papillomavirus-Related Cancer Vaccine Strategies

Human papillomavirus (HPV) persistent infection is a major pathogenic factor for HPV-related cancers, such as cervical cancer (CC), vaginal cancer, vulvar cancer, anal cancer, penile cancer, and head and neck cancer (HNC). Since the introduction of the world's first prophylactic HPV vaccine, there has been a decline in the incidence of HPV infections and associated cancers. This article reviews the latest literature on the research progress, efficacy, and safety of HPV vaccines for these cancers, providing a reference for HPV vaccination strategy.

By utilizing databases such as PubMed, Google Scholar, CNKI, and Wanfang, we conducted a literature search on research papers related to HPV vaccines from 2014 to 2024, employing keywords such as "HPV", "HPV vaccine", "CC", "vaginal cancer", "vulvar cancer", "anal cancer", "penile cancer" and "HNC". Additionally, we reviewed the latest information available on official websites, including the World Health Organization (WHO). Based on the quality and relevance of the papers, we selected over 100 of the most representative articles for further summarization and analysis.

Vaccination against HPV can effectively block the transmission of the virus and prevent HPV-related cancers. Current studies have confirmed the efficacy and safety of prophylactic HPV vaccination. However, numerous challenges remain. The global vaccination rate for preventive vaccines remains low, particularly in low- and middle-income countries. Nonetheless, in the future, we can enhance the accessibility, affordability, and coverage of HPV vaccines by expanding the indications of already licensed vaccines, continuously developing new vaccines.

The HPV vaccine is an extremely effective measure for the prevention and treatment of HPV-related cancers. Although there are many challenges in expanding the coverage of the HPV vaccine. It is believed that in the not-too-distant future, both prophylactic and therapeutic HPV vaccines will achieve commendable results.